Position in ALNY
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$266,411
-$158,756 QoQ
Shares Held
885
-31.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#560
of 784 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Sava Infond d.o.o. holds $3,615,991 across 6 Biotechnology names. ALNY ranks #5 (7.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
4,200 | $1,012,074 | |
| 2 | RPRX |
Royalty Pharma plc
|
16,960 | $950,947 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,350 | $670,585 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
850 | $530,009 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
885 | $266,411 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
3,250 | $185,965 |
All Filings in ALNY
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $266,411 | 885 | Shares | Defined | 2026-07-16 | |
| 2026-03-31 | $425,167 | 1,285 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $510,980 | 1,285 | Shares | Defined | 2026-01-29 | |
| 2025-09-30 | $747,840 | 1,640 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $710,876 | 2,180 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $561,641 | 2,080 | Shares | Sole | 2025-04-23 | |
| 2024-12-31 | $407,086 | 1,730 | Shares | Sole | 2025-02-12 | |
| No filing history on record for this holder in this stock. | ||||||